Wednesday, June 8, 2022 Daily Archives

Transform Your AAV Analytics With Mass Photometry

by

This webcast features: Gareth Rogers, Product Manager, Refeyn, and Kirsty McManus, Senior Scientist, Characterization Team, Pharmaron Biologics. Mass photometry is a novel, easy-to-use bioanalytical technology that measures the empty-full AAV capsid ratio in minutes using minimal sample amounts and without the need for sample preparation. Circumventing the requirement of large capital expense and skilled operators, it can be employed in different AAV workflows. In this webinar, we present a novel mass photometry instrument called SamuxMP, which is dedicated to the…

June 8, 2022

Resilience continues capacity march with further $625m of funding

by

National Resilience has raised $1.225 billion in financing over the past 10 months and intends to use it to further build out its biomanufacturing and R&D network. (National) Resilience launched in November 2019 through $800 million of capital with ambitions to provide “new, better, faster ways” to manufacture advanced therapies. Over the past two-and-a-half years, the firm has moved beyond cell and gene therapies and now offers manufacturing services across multiple modalities through a mushrooming production and R&D infrastructure. Through…

June 8, 2022

Seqirus completes $156m expansion at NC flu vaccine plant

by

Completion of the four-year $156 million expansion at its Holly Springs, North Carolina plant will support cell-based influenza vaccine production, says Seqirus.  Seqirus said that its newly installed pre-filled syringe line has received US Food and Drug Administration (FDA) approval and will support influenza vaccine production for 2022 and 2023 Northern Hemisphere season and beyond. Additionally, the firm claims the expansion increases the site’s ability to respond to an influenza pandemic and that its Holly Springs facility is the largest…

June 8, 2022

Emergent claims J&J owes up to $420m in vaccine contract breach

by

J&J has terminated a COVID-19 vaccine contract because of breaches in GMP compliance at CDMO Emergent BioSolutions. J&J’s Janssen entered into an agreement with Emergent BioSolutions in 2020 for the manufacture of its viral vector-based COVID-19 vaccine. However, the contract development and manufacturing organization (CDMO) has been hit with numerous quality issues at its Bayview, Maryland facility causing an ingredient mix up and culminating in the destruction of nearly 400 million doses of vaccines, according to a recent US Government…

June 8, 2022